Literature DB >> 1947432

Inhibition of glycopeptidolipid synthesis resulting from treatment of Mycobacterium avium with 2-deoxy-D-glucose.

E L Wright1, W W Barrow.   

Abstract

Exponentially growing cultures of Mycobacterium avium complex serovar 4 were treated with 2-deoxy-D-glucose (2-DDG) and incubated with radiolabelled components which incorporate into the serovar-specific glycopeptidolipids (GPL) associated with the L1 layer. Following treatment with the drug, radiolabelled lipids were extracted from the mycobacteria and examined by thin-layer chromatography, high performance liquid chromatography and autoradiography to determine the percent distribution of radioactivity in the GPL and other related lipids. Treatment of serovar 4 with 2-DDG resulted in a dose-dependent inhibition of GPL biosynthesis, as judged by a reduction in the incorporation of radiolabelled phenylalanine, mannose and methionine into the GPL. In addition, a concomitant accumulation of at least two phenylalanine-containing lipopeptides was observed in cells treated with 2-DDG. Cultivation of serovar 4 in the presence of 2-deoxy-D-1,2-(3)H-glucose did not result in internal radiolabelling of the GPL, indicating that 2-DDG was not being incorporated into the GPL as an analogue of mannose, but rather was acting as a metabolic inhibitor of GPL biosynthesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1947432     DOI: 10.1016/0923-2508(91)90193-e

Source DB:  PubMed          Journal:  Res Microbiol        ISSN: 0923-2508            Impact factor:   3.992


  8 in total

1.  Cell-free system responsible for internal radiolabeling of glycopeptidolipids of the Mycobacterium avium complex.

Authors:  N Ramasesh; E L Wright; W W Barrow
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

2.  Modified lymphocyte response to mitogens induced by the lipopeptide fragment derived from Mycobacterium avium serovar-specific glycopeptidolipids.

Authors:  S K Tassell; M Pourshafie; E L Wright; M G Richmond; W W Barrow
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

3.  Monoclonal infection involving Mycobacterium avium presenting with three distinct colony morphotypes.

Authors:  E L Wright; S Zywno-van Ginkel; N Rastogi; W W Barrow
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

4.  Immunomodulatory spectrum of lipids associated with Mycobacterium avium serovar 8.

Authors:  W W Barrow; T L Davis; E L Wright; V Labrousse; M Bachelet; N Rastogi
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

5.  Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against Mycobacterium avium.

Authors:  W W Barrow; E L Wright; K S Goh; N Rastogi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  Comparative effects of Mycobacterium avium glycopeptidolipid and lipopeptide fragment on the function and ultrastructure of mononuclear cells.

Authors:  M Pourshafie; Q Ayub; W W Barrow
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

7.  Immunomodulation of human peripheral blood mononuclear cell functions by defined lipid fractions of Mycobacterium avium.

Authors:  W W Barrow; J P de Sousa; T L Davis; E L Wright; M Bachelet; N Rastogi
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

8.  Potential drug targets for Mycobacterium avium defined by radiometric drug-inhibitor combination techniques.

Authors:  N Rastogi; K S Goh; E L Wright; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.